Skip to main content

Table 3 Genetic polymorphisms in combination of ERCC1 and XRCC1 and survival of patients

From: Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma

Stage

Combined genotype

Patients(%)

MST(mon)

Log-rank P

HR(95%CI)a

all

0 variant

67(26.1)

25.10

 

1.00

 

1 variant allele

100(38.9)

13.07

 

1.52(1.04-2.22)

 

2 variant alleles

58(22.6)

9.27

< 0.001

2.33(1.54-3.50)

 

3 variant alleles

26(10.1)

6.30

 

2.98(1.76-5.04)

 

4 variant alleles

6(2.3)

3.87

 

9.24(3.50-24.44)

I and II

0 variant

26(33.3)

45.80

 

1.00

 

1 variant allele

30(38.5)

22.27

 

1.98(0.86-4.58)

 

2 variant alleles

14(17.9)

11.60

0.145

2.81(1.10-7.13)

 

3 variant alleles

6(7.7)

--b

 

1.41(0.26-6.75)

 

4 variant alleles

2 (2.6)

17.27

 

9.05(1.04-78.76)

III and IV

0 variant

41(22.9)

19.10

 

1.00

 

1 variant allele

70(39.1)

11.17

 

1.54(0.98-2.39)

 

2 variant alleles

44(24.6)

8.93

< 0.001

2.29(1.44-3.66)

 

3 variant alleles

20(11.2)

5.83

 

3.69(2.06-6.62)

 

4 variant alleles

4(2.2)

3.63

 

18.50(5.68-60.23)

  1. Abbreviation: MST, median survival time; HR, hazard ratio; CI, confidence interval.
  2. aHR adjusted for age, stage, surgical operation and chemotherapy or radiotherapy.
  3. bMST for this genotype could not be calculated.